In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment

Journal of Controlled Release : Official Journal of the Controlled Release Society
Burcin YavuzBill Chiu

Abstract

High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment. Different concentrations of silk, a biodegradable, non-toxic, non-immunogenic material were employed to prepare etoposide-loaded wafer formulations. Secondary structure of silk in the formulations was characterized using Fourier Transform Infrared (FTIR) spectroscopy and optimized based on the crystalline structure. Accelerated in vitro degradation studies under different conditions such as acidic, alkaline, oxidizing mediums and high temperature, were performed. The integrity of the silk wafer structure was maintained unless exposed to 0.1 N NaOH for 24 h. In vitro release of etoposide was performed in PBS (phosphate buffered saline) at 37 °C. Silk coated 6% wafers released the drug up to 45 days, while uncoated wafers released the drug for 30 days. Cytotoxicity study was performed on KELLY cells to evaluate the etoposide cytotoxicity (LC50) and the long-term efficacy of the etoposide wafer formulations. The results showed that etoposide killed 50% of the cells at 1 μg/mL concentration and the wafer ...Continue Reading

References

Jan 1, 1994·Cancer Chemotherapy and Pharmacology·S P JoelM L Slevin
Sep 28, 1998·Biochimica Et Biophysica Acta·K R Hande
Dec 29, 2004·Biomaterials·Rebecca L HoranGregory H Altman
Feb 7, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·S HofmannL Meinel
May 30, 2006·Molecular Cancer Therapeutics·Leo E GerweckSergey Kozin
Dec 15, 2006·Cancer Letters·Alessandra Montecucco, Giuseppe Biamonti
Jun 26, 2007·Lancet·John M MarisSusan L Cohn
Oct 17, 2007·Current Oncology·J PerryN Laperriere
May 27, 2008·Biomaterials·Yongzhong WangDavid L Kaplan
Jan 1, 2007·Progress in Polymer Science·Charu Vepari, David L Kaplan
May 14, 2010·AAPS PharmSciTech·Jayesh JainVandana Patravale
Jan 15, 2011·Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics·Zhao Qin, Markus J Buehler
Oct 1, 2011·Nature Protocols·Danielle N RockwoodDavid L Kaplan
Dec 14, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jesse B WolinskyMark W Grinstaff
Mar 2, 2012·Pediatric Blood & Cancer·Peter E ZageSusan L Cohn
Aug 2, 2012·International Journal of Environmental Research and Public Health·Sachiko Ezoe
Apr 30, 2013·Advanced Healthcare Materials·F Philipp SeibDavid L Kaplan
May 7, 2013·Advanced Functional Materials·F Philipp SeibDavid L Kaplan
Apr 24, 2014·Cancer Biology & Therapy·Brandon S BrownEnnio Tasciotti
Jul 11, 2014·Biomaterials·Tuna YucelDavid L Kaplan
Oct 27, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jeannine M CoburnDavid L Kaplan
Nov 4, 2016·International Journal of Cancer. Journal International Du Cancer·Jeannine CoburnBill Chiu
Feb 10, 2017·Journal of Biomedical Science·Maria Rosaria EspositoGian Paolo Tonini
Mar 9, 2018·AAPS PharmSciTech·Ana Gabriela Reis SolanoGérson Antônio Pianetti

❮ Previous
Next ❯

Citations

Jun 22, 2019·Expert Opinion on Drug Delivery·Burcin YavuzDavid L Kaplan
Aug 1, 2020·Journal of Cellular Physiology·Taranom MobasheriNima Rezaei
Sep 10, 2020·BMC Biomedical Engineering·Kimberly J Ornell, Jeannine M Coburn
Feb 17, 2019·Acta Biomaterialia·David G LeachJeffrey D Hartgerink
Aug 25, 2020·ACS Applied Bio Materials·Burcin YavuzDavid L Kaplan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomaterial Engineering

Advances in biomaterial engineering have permitted the development of sophisticated drug-releasing materials with a biomimetic 3D support that allow a better control of the microenvironment of transplanted cells. Here is the latest research.

© 2022 Meta ULC. All rights reserved